Literature DB >> 7990143

TEM beta-lactamase mutants hydrolysing third-generation cephalosporins. A kinetic and molecular modelling analysis.

X Raquet1, J Lamotte-Brasseur, E Fonzé, S Goussard, P Courvalin, J M Frère.   

Abstract

The catalytic properties of six "natural" mutants of the TEM-1 beta-lactamase have been studied in detail, with special emphasis on their activity versus third-generation cephalosporins. On the basis of the recently determined high-resolution structure of the wild-type enzyme, and of the substrates' structures optimized by the AMI quantum chemistry method, we have attempted to explain the influences of the mutations on the substrate profiles of the enzymes. Some of the kinetic results have thus received a satisfactory, semi-quantitative interpretation, especially in the case of single mutations. Analysis of the double mutants proved more hazardous. Extending the comparison to some other class A beta-lactamases showed that similar properties could result from different sequences, supplying an interesting example of convergent evolution within a generally diverging family.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990143     DOI: 10.1006/jmbi.1994.1756

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  57 in total

1.  Single-domain antibody fragments with high conformational stability.

Authors:  Mireille Dumoulin; Katja Conrath; Annemie Van Meirhaeghe; Filip Meersman; Karel Heremans; Leon G J Frenken; Serge Muyldermans; Lode Wyns; Andre Matagne
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  CENTA as a chromogenic substrate for studying beta-lactamases.

Authors:  C Bebrone; C Moali; F Mahy; S Rival; J D Docquier; G M Rossolini; J Fastrez; R F Pratt; J M Frère; M Galleni
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Biochemical characterization of TEM-92 extended-spectrum beta-lactamase, a protein differing from TEM-52 in the signal peptide.

Authors:  Mariagrazia Perilli; Bernardetta Segatore; Maria Rosaria De Massis; Laura Pagani; Francesco Luzzaro; Gian Maria Rossolini; Gianfranco Amicosante
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Biochemical characterization of laboratory mutants of extended-spectrum beta-lactamase TEM-60.

Authors:  Bibiana Caporale; Nicola Franceschini; Mariagrazia Perilli; Bernardetta Segatore; Gian Maria Rossolini; Gianfranco Amicosante
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1.

Authors:  Akiko Shimizu-Ibuka; Mika Oishi; Shoko Yamada; Yoshikazu Ishii; Kiyoshi Mura; Hiroshi Sakai; Hiroshi Matsuzawa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

6.  The bla gene of the cephamycin cluster of Streptomyces clavuligerus encodes a class A beta-lactamase of low enzymatic activity.

Authors:  F Pérez-Llarena; J F Martín; M Galleni; J J Coque; J L Fuente; J M Frère; P Liras
Journal:  J Bacteriol       Date:  1997-10       Impact factor: 3.490

7.  Active TEM-1 beta-lactamase mutants with random peptides inserted in three contiguous surface loops.

Authors:  Pascale Mathonet; Julie Deherve; Patrice Soumillion; Jacques Fastrez
Journal:  Protein Sci       Date:  2006-09-08       Impact factor: 6.725

8.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

9.  High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognition.

Authors:  Pierre-Yves De Wals; Nicolas Doucet; Joelle N Pelletier
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

Review 10.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.